This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.
The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally-invasive liquid biopsies. SeroTag analyses autoantibodies—some of the most stable analytes—and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.
The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune’s NavigAID disease-specific stratification panels—precision medicine tools which are enabling patient and disease stratification and support therapeutic development.
The pathology of autoimmune diseases is intricate, and is characterised by a complex, maladaptive response of the immune system. This underlying process provides us with a window of opportunity, as autoantibodies are often produced early during the development of autoimmune diseases (sometimes even years before diagnosis), which can often provide insights into how a disease will manifest and progress. The advance warning signs given by autoantiantibodies makes them the biomarker of choice for autoimmune diseases.
To date, autoantibodies have not been analysed systematically in this field, and their potential to define the status of a patient’s immune-competence and responsiveness to treatment remains largely untapped.
Ocimmune is applying its SeroTag platform to identify novel biomarkers, enabling patient subgrouping within autoimmune diseases—thereby supporting the successful development of therapies.
As a result of its SeroTag work, Oncimmune has already developed the NavigAID range of stratification arrays for a number of indications, such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s Disease (SjS) and others.
In addition, SeroTag has also been used for the development of a number of in vitro diagnostic products for multiple autoimmune indications, such as the Multilisa BICD2 panel for SSc. This forms part of Oncimmune’s unique cascade, from initial discovery through validation and commercialisation.
The activity of autoantibodies in patients set to receive, or currently receiving, cancer immunotherapy offers a unique opportunity to support the development of safer, more effective immuno-oncology treatments.
Although the significance of autoantibodies in immuno-oncology is now being recognised, a systematic analysis has yet to be performed. Such autoantibody discovery and the immuno-profiling of patients holds great promise to address challenges such as cancer immunotherapy response prediction, as well as the prediction and monitoring of irAEs.
SeroTag is currently being used to do exactly this. In line with our work in autoimmune diseases, SeroTag enables the discovery and development of minimally-invasive liquid biopsy biomarkers, which is helping to expand Oncimmune’s NavigAID offering to support the development of immunotherapeutic anticancer drugs.
Through our partnerships and strategic collaborations with world-leading institutes such as the National Center for Tumor Diseases (NCT) in Germany, the National Cancer Institute (NCI) in the USA and Gustave Roussy (GR) in France, we have already successfully applied SeroTag to a number of indications and immunotherapies and have been able to demonstrate that the platform is enabling the immuno-profiling of IO patients.